Biomarker, Chronic obstructive pulmonary disease, Matrix Metalloproteinase-9, mRNA expression, SYBR green https://mc06.manuscriptcentral.com/bcb-pubs (FEV1) is considered to be the main diagnostic measure for COPD, yet it is insufficiently sensitive to monitor disease progression. Biomarkers capable of monitoring COPD progression and severity are needed. In this report, we evaluated matrix metalloproteinase-9 (MMP-9) as an early marker for the detection and staging of COPD, by assessing the mRNA levels of MMP-9 in peripheral blood samples collected from 22 COPD patients, 6 asymptomatic smokers and 5 healthy controls. Our results demonstrate that the mRNA levels of MMP-9 increased more than two-folds in severe COPD relative to non-COPD smokers or moderate COPD groups. Moreover, in the very severe COPD group, MMP-9 mRNA levels showed a 4-fold increase relative to the non-COPD smokers or the moderate COPD groups, while there was a mild increase (~ 40%) when compared to the severe COPD group. Taken together, our results suggest that MMP-9 serves as a biomarker for the grade and severity of COPD.
Introduction
COPD is a collective term describing two separate chronic lung diseases that adversely affect airflow: chronic bronchitis and emphysema (Ning et al. 2004 ). COPD typically develops over the course of many years (Cosio et al. 2009; Bruce and McEvoy 2007) . COPD is presently the fourth leading cause of death worldwide, but the world health organization (WHO) predicts that it will become the third leading cause of death by 2030 (WHO, 2008) . Many people suffer from this disease for years, and die prematurely from it or from its complications (Decramer et al. 2012; GOLD 2011) . Prevalence surveys suggest that almost one quarter of adults aged 40 years and older have mild airflow obstruction (Mannino and Buist 2007; Buist et al. 2007; and Menezes et al. 2005) .
COPD risk factors are actively studied. Smoking is the major risk factor and the predominant cause of COPD, and is implicated in 90 % of COPD cases (Bruce and McEvoy 2007; and Doherty 2002) . However, only 10-20 % of the smokers develop COPD, pointing to one or more additional risk factor, such as genetic susceptibility. Several genes have been identified as modifiers of individual susceptibility to COPD, such as the genes encoding proteases (e.g. Matrix Metalloproteinases (MMP S )), anti-proteases (e.g. alpha-1-antitrypsin (A1A)), inflammatory mediators (e.g. interleukin-2), proteins with antioxidant properties (e.g. extracellular superoxide dismutase (SOD)), enzymes that metabolize xenobiotic compounds (e.g. Glutathione-S-transferases (GST S )) and proinflammatory mediator such as tumor necrosis factor-α (TNF-α) (Molfino and Jeffery 2006; Hirvonen 2009; Harrison et al., D r a f t 4 COPD is frequently underdiagnosed due to the lack of definitive diagnostic biomarkers. The major marker utilized to monitor COPD patients is "forced expiratory volume in the first second (FEV1)" (D'Armiento et al. 2009 ). FEV1 is used to diagnose the stage of COPD and to predict COPD mortality (Decramer et al. 2005) . Taking into consideration that COPD onset is relatively asymptomatic, patients that are at risk or in the early stages of the disease are not usually monitored by FEV1 measurements. As a result, COPD is typically diagnosed only after disease progression (Rabe et al. 2007) . Consequently, there is a considerable need for new reliable and reproducible markers specific to COPD that are able to diagnose disease severeity and foretell progression (D'Armiento et al. 2009 ).
Matrix MetalloProteinases are prominent proteolytic molecules released by neutrophils and alveolar macrophages during the inflammatory events in COPD. which is the predominant protease in alveolar tissues, has received considerable attention among many MMPs, due to its ease of detection and quantification, suggesting it could be used as a COPD biomarker (Kumar et al. 2011) . MMP-9 is a zinc dependent endopeptidase that is involved in an array of normal and pathological processes including remodeling of extracellular matrix (ECM), development, inflammatory response, and carcinoma progression (Muroski et al. 2008) . MMP-9 is synthesized and secreted in monomeric form as a zymogen D r a f t 5 and neutrophils that act as facilitators of the inflammatory response. MMP-9 also inactivates Alpha-1-Antitrypsin, which typically serves a protective function by inhibiting Neutrophil Elastase, as it is also able to cleave elastin, a crucial structural component of the lungs. Taken together, these mechanisms support roles for MMP-9 as a critical mediator in COPD.
The current study aims to evaluate MMP-9 as biomarker for COPD early detection and staging by comparing its relative mRNA expression levels isolated from peripheral blood white blood cells of normal, asymptomatic smokers, moderate COPD, severe COPD and very severe COPD patients. The data presented in this report support the use of MMP-9 as a biomarker to differentiate between moderate, severe and very severe COPD. However, our results suggest that MMP-9 mRNA levels cannot be used for early detection of the disease. D r a f t 6 was less than 30%. The selected COPD subjects were not diagnosed with any coexisting pulmonary diseases, like; bronchiectasis, tuberculosis, asthma, or lung cancer.
The study was approved by the local research ethics committee and was performed in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards, and all subjects signed written informed consent.
II. Methods

Lung function testing
The FEV1, forced vital capacity (FVC), and FEV1/FVC ratio were determined using a Jaeger spirometer and were performed at the Chest Department at Ain Shams University Hospitals. Values are expressed as percentages of the predicted normal values for age, sex, and height according to the European Community for Steel and Coal guidelines (Quanjer 1983; Sherril et al. 1992) .
White blood cells isolation, total RNA preparation and cDNA synthesis
White blood cells were isolated from blood according to McCoy 1998. Blood samples (4 ml) were collected using heparin vacationer tubes followed by addition of 10 ml red blood cells lysis buffer (10 mM KHCO 3, 150 mMNH 4 Cl, 1 mM EDTA). The mixture was incubated for 10 min at RT, followed by centrifugation for 5 min at 2,000 rpm. Following centrifugation, the cleared supernatant was discarded and the cells were washed twice using 1 ml PBS followed by centrifugation for 5 min at 2,000 rpm (McCoy 1998). The recovered white blood cells pellet were ruptured in 1 ml Biozol® reagent (BioRad Cat.# 161-0100), and total RNA was extracted according to the manufacturer's recommendations.
Reverse transcription of the extracted RNA (1 µg) was carried out using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific* Fermentas Cat # K1612) according to the manufacturer's recommendations.
Primers
Primers (Table 1 ) used in this study to amplify matrix metalloproteinase-9 (MMP-9) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed using BLAST tool.
Conventional PCR detection of MMP-9 and GAPDH mRNA
The conventional PCR for MMP-9 and GAPDH was performed in 25 µl reaction curves generated by incubating the products for 1 min at 95°C, followed by 30 sec at 55°C
and finally 30 sec at 95°C. Data were analyzed using the MXpro QPCR software (Agilent Technologies) to estimate cycle threshold (C T ) values and dissociation curves to estimate the optimal melting temperatures for all reactions. In all experiments, we included two additional negative controls: 1) RT-control, which consisted of a PCR reaction lacking reverse transcriptase, and 2) a no template control (NTC), which used water in place of the cDNA template.
Statistical analysis
Fold change in gene expression ( . Differences in the numerical data between every two groups were evaluated using Mann-Whitney U test, and between the five groups using Kruskal Wallis test. The significance among the groups was compared at the level of significance P=0.05 as follows:
P<0.05 = significant, P< 0.01 or 0.001 = highly significant, and P > 0.05 = non-significant (NS).
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Results
Conventional PCR analysis
Conventional PCR was carried out on the 33 cDNA samples followed by agarose electrophoresis prior to qPCR to check the quality of the cDNA samples, and to assess the specificity of the primer pairs designed for the 2 genes under study, GAPDH and MMP-9.
The data presented in figures 1 illustrates results of agarose gel electrophoresis for PCR amplifications of GAPDH (amplicon size=150 bp) and MMP-9 (amplicon size=136 bp) using the specific primers noted in table 1. The results suggested that the primer sets for GAPDH and MMP-9 were specific, and that the cDNA preparation did not have any genomic DNA contamination.
MMP-9 expression measurements
Gene amplification curves from RT-PCR of MMP-9 and GAPDH cDNA shown in for the non-COPD smoking group, moderate COPD group, the severe COPD group, and the very severe COPD group as described in Material and Methods.
The data presented in table 3 and figure 4 showed variations in the mean FEG values between the three COPD grades (moderate, severe and very severe) with a trend suggesting the greater the decline in FEV 1 , the greater the MMP-9 expression. No significant variation in MMP-9 expression levels was observed between the non-COPD smokers (0.44±0.2) and the moderate COPD groups (0.39±0.15). In both of these groups, MMP-9 levels were similarly down-regulated relative to the very severe COPD group. The MMP-9 level of expression in severe COPD group (1.13±0.12) increased more than two-fold compared to the non-COPD D r a f t smokers and the moderate COPD groups. In addition, the MMP-9 level of expression in the very severe COPD group (1.66±0.55) increased more than four-fold compared to the non-COPD smokers and the moderate COPD groups. Finally, there was an ~40% increase in MMP-9 levels observed in the moderate COPD group compared to the severe COPD group.
Differences in MMP-9 FGE were compared between every two studied groups using
Mann-Whitney U test and between the five tested groups using Kruskal Wallis test, and significant differences are summarized in table 3. A highly significant increase of MMP-9 FGE between the non-COPD smokers vs the severe COPD group (P = 0.003 < 0.01), the non-COPD smokers vs the very severe COPD group (P = 0.003 < 0.01), the moderate COPD group vs the severe COPD group (P = 0.001< 0.01), the moderate COPD group vs the very severe COPD group (P = 0.001 < 0.01)); and the severe COPD group vs the very severe COPD group (P = 0.021 < 0.05) was observed, while the Kruskal Wallis test showed a significant change in MMP-9 FGE among the four studied groups.
Discussion
COPD is a condition primarily caused by the inhalation of noxious particles or gases (usually cigarette smoke) leading to inflammation and remodeling in the large and small airways, and destruction of the lung parenchyma leading to emphysema. COPD diagnosis and severity are assessed by spirometric measurements (FEV1, FEV1/FVC ratio). However, there is a considerable evidence supporting the view that COPD is under-diagnosis, especially in the mild and moderate groups, and that FEV1 is an insufficiently sensitive biomarker to accurately diagnose the very early onset of disease (Nicholas 2013 2003) . MMP-9 is secreted along with its inhibitor TIMP-1 which can bind to both the inactive and active form of MMP-9 (Ram et al. 2004) . Although many MMPs have been proposed to play a role in lung pathology, MMP-9 has received a considerable attention concerning its relationship to COPD identification, diagnosis, pathogenesis, and disease management (Engstrom et al. 2012; Dickens et al. 2011; Kumar et al. 2011; and Koczulla et al. 2012 ).
Compared to healthy controls, COPD patients display increased protein levels of MMP-9
were reported in sputum, plasma and serum (Brajer et al. 2008; Kang et al. 2003) . Monocytes from COPD patients also have increased activity as these releases more MMP-9 but less IL-8 than control subjects (Aldonyte et al. 2003) . The MMP-9/TIMP-1 ratio positively correlates with FEV1 in COPD patients, who have low FEV1, have lower ratios than control subjects (Higashimoto et al. 2005 and Vignola et al. 1998 ).
In the current study, we determined that MMP-9 expression levels varied significantly between moderate, severe, and very severe COPD patients, relative to healthy non-smoking controls. However, up-regulation of MMP-9 observed only in severe and very severe COPD expression in severe to very severe COPD grades as compared to moderate COPD and non-COPD smokers. In contrast, MMP-9 expression did not differ between moderate COPD and non-COPD smokers. These findings are consistent with our observations; since we also noticed a significant increase in MMP-9 expression in the severe COPD group, which was further enhanced in the very sever COPD group. In contrast, we failed to observe a significant difference in MMP-9 expression between moderate COPD patients and non-COPD smokers (Llinas et al. 2011) . On the other hand, while MMP-9 over-expression was the general response observed in this study, MMP-9 down-regulation was also observed in non-COPD smokers and moderate COPD patients. A similar observation reported by Churg et al. 2012, while a drop in MMP-9 expression observed in mice chronically exposed to cigarette smoke condensate as compared to air-exposed mice (Churg et al. 2012) . However, different results were reported with MMP-9 knockout mice. These mice showed a similar inflammatory response profile and developed the same severity of cigarette smoke induced emphysema as did strain-matched wild-type mice. This study demonstrated that MMP-9 D r a f t 13 mRNA levels did not correlate with markers of continuing lung damage or with local degrees of emphysema (Atkinson et al. 2011) .
To explain the down-regulation of MMP-9 expression levels observed in the current study, one can speculate that the defense mechanisms fostered by the human body to face the primary smoking-induced elevation of MMP-9 expression may be strong enough to cause temporary down-regulation of MMP-9, as observed in moderate COPD and asymptomatic smoking individuals. Meanwhile, the increase in production of interferon-gamma (INF-γ), as one of the responses to smoke exposure, causes a reduction in MMP-9 expression (Sanceau et al. 2002; Spira et al. 2004; Golpon et al. 2004) . However, continuous exposure of lungs to noxious particles in cigarette smoke accompanied by continuous release of free radicals and accelerated inflammatory responses would cause deterioration in the body defense mechanisms in favor of increasing MMP-9 expression, which was observed in the severe and the very severe COPD grades. In conclusion, this work represents a reproducible, convenient and simple method for use of MMP-9 as a biomarker for the COPD progression. MMP-9 can be relied upon to determine the grade and severity of COPD. However, the validity of this marker for early diagnosis of the disease is questionable. The same approach can be used to identify other biomarker that may be used for early and reliable detection of COPD. D r a f t 
Gene
Primer sequence GAPDH-Forward 5'-GAAGGTCGGAGTCAACGGATTT-3' GAPDH-Reverse 5'-CATGGGTGGAATCATATTGGAAC-3' MMP-9-Forward 5'-CGGCGCCTCTGGAGGTTCG-3' MMP-9-Reverse 5'-GCAGAAATAGGCTTTCTCTCGG-3' 
